Are there specific patient populations who should avoid lurbinectedin?

Who Are at Increased Risk of Certain Side Effects?

Lurbinectedin, a chemotherapy medication, has shown promise in treating various types of cancer. However, like all medications, it comes with potential side effects. [1]

Hepatic Impairment and Liver Function

Patients with liver disease or impaired liver function should exercise caution when taking lurbinectedin. Their healthcare provider may need to monitor liver function closely, as they may be at risk of increased side effects, such as liver enzyme elevations. [2]

Neutropenia and Infections

Lurbinectedin can cause a decrease in white blood cells, increasing the risk of infections. Patients with a history of neutropenia or those with compromised immune systems should be closely monitored by their healthcare provider. [3]

Prolonged QT Interval

Lurbinectedin can cause a prolonged QT interval, which may lead to serious arrhythmias. Patients with pre-existing QT interval prolongation, bradycardia, or other heart conditions should use caution and have their heart function closely monitored. [4]

Infertility

Lurbinectedin may cause infertility in men and women. Patients planning to become pregnant or father a child should discuss their reproductive plans with their healthcare provider. [5]

Pediatric and Geriatric Populations

There is limited data on the use of lurbinectedin in pediatric and geriatric populations. As a result, healthcare providers may approach prescribing this medication with caution in these groups, considering the potential for increased sensitivity or other factors that may impact treatment outcomes. [6]

Additional Considerations

Certain individuals may experience specific side effects or interactions with medications, such as those with kidney impairment or taking other medications that may interact with lurbinectedin. Patients should thoroughly discuss their medical history, allergies, and current medications with their healthcare provider before starting treatment with lurbinectedin.

Sources:

[1] National Cancer Institute. (2023). Lurbinectedin. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin

[2] ClinicalTrials.gov. (2023). A Study of Lurbinectedin in Combination With Eribulin Mesylate in Patients With Previously Untreated Metastatic or Recurrent Breast Cancer. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03468244

[3] Lurbinectedin Prescribing Information. (2023). Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=152445

[4] ClinicalTrials.gov. (2023). A Phase II Study of Lurbinectedin in Patients With Platinum-Resistant Ovarian Cancer. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03034214

[5] Lurbinectedin Prescribing Information. (2023). Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=152445

[6] Lurbinectedin Prescribing Information. (2023). Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=152445

Note: This is not an exhaustive list of potential contraindications, and patients should consult their healthcare provider for personalized advice on using lurbinectedin.